Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
AstraZeneca
Merck
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Esmirtazapine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Esmirtazapine?

Esmirtazapine is an investigational drug.

There have been 9 clinical trials for Esmirtazapine. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2004.

The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Mental Disorders, and Dyssomnias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Parexel, and [disabled in preview].

Recent Clinical Trials for Esmirtazapine
TitleSponsorPhase
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)Merck Sharp & Dohme Corp.Phase 3
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)Merck Sharp & Dohme Corp.Phase 3
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)Merck Sharp & Dohme Corp.Phase 3

See all Esmirtazapine clinical trials

Clinical Trial Summary for Esmirtazapine

Top disease conditions for Esmirtazapine
Top clinical trial sponsors for Esmirtazapine

See all Esmirtazapine clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Moodys
Mallinckrodt
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.